Covid-19 Vaccine Market By Technology (mRNA Technology, Viral Vector Technology), Application (Primary Vaccination, Booster Doses), & Region for 2026-2032

Covid-19 Vaccine Market Valuation - 2026-2032

Growing public understanding of vaccine benefits, leading to higher demand for COVID-19 vaccinations. Increased funding and support from governments and organizations to promote vaccination efforts worldwide is driving the market size surpass USD 7.64 Billion valued in 2024 to reach a valuation of around USD 12.64 Billion by 2032.

In addition to this, innovations in vaccine development and delivery methods enhancing production efficiency and distribution is spurring up the adoption of Covid-19 vaccine. Partnerships between pharmaceutical companies, governments, and NGOs accelerating research and distribution efforts is enabling the market to grow at a CAGR of 7.16% from 2026 to 2032.

Covid-19 Vaccine Market: Definition/ Overview

A COVID-19 vaccine is a biological preparation designed to provide immunity against the SARS-CoV-2 virus, which causes COVID-19. These vaccines work by introducing a harmless component of the virus, such as a spike protein or mRNA, into the body. This triggers the immune system to recognize and respond to the virus if exposed in the future, helping to prevent severe illness and transmission.

The application of COVID-19 vaccines has been crucial in controlling the pandemic. Vaccination campaigns have aimed to achieve widespread immunity in populations, significantly reducing hospitalization rates and deaths associated with the virus. In addition to individual protection, widespread vaccination contributes to herd immunity, helping to limit the virus's spread and facilitating the return to normal societal functions.

How will Growing Focus on Pediatric Vaccinations Increase Adoption of Covid-19 Vaccine?

Rising global vaccination rates have propelled the Covid-19 vaccine market forward, with governments worldwide implementing comprehensive immunization programs. According to the WHO, as of December 2023, over 13.5 billion Covid-19 vaccine doses had been administered globally, demonstrating massive market penetration. The emergence of new variants continues to drive demand for updated formulations, while health organizations emphasize the importance of booster doses for vulnerable populations.

Technological advancements in vaccine platforms have revolutionized the market landscape, particularly through mRNA technology. The US CDC reported that mRNA vaccines showed over 90% efficacy in preventing severe Covid-19 cases during initial trials in 2020-2021. In September 2023, Pfizer and Moderna launched their updated monovalent XBB.1.5 vaccines, targeting newer Omicron subvariants and expanding their market presence.

Growing focus on pediatric vaccinations and specialized formulations for immunocompromised individuals has created new market opportunities. The European Medicines Agency (EMA) data showed that approximately 82% of children aged 12-17 in the EU/EEA received at least one Covid-19 vaccine dose by mid-2023. Recently, Novavax announced successful trials of its combination Covid-19-influenza vaccine in March 2024, potentially revolutionizing the seasonal vaccination approach and expanding market possibilities.

How Supply Chain Disruptions Hampering Covid-19 Vaccine Market Growth?

The COVID-19 vaccine market faces several restraints that can impact its growth and accessibility. One major constraint is vaccine hesitancy, where individuals may be reluctant or refuse to receive the vaccine due to misinformation, fear of side effects, or distrust in pharmaceutical companies. This hesitancy can lead to lower vaccination rates, undermining public health efforts and prolonging the pandemic.

Supply chain disruptions have also posed significant challenges to the COVID-19 vaccine market. The rapid development and deployment of vaccines put immense pressure on manufacturing and distribution networks. Factors such as shortages of raw materials, transportation issues, and logistical challenges can lead to delays in vaccine availability, particularly in low- and middle-income countries.

Regulatory hurdles represent another restraint, as vaccine developers must navigate complex approval processes in various countries. Differences in regulatory standards can slow down the introduction of new vaccines and limit market expansion. Additionally, ongoing surveillance and post-marketing studies are necessary to monitor vaccine safety and efficacy, which can further complicate the approval process.

Category-Wise Acumens

Will Rise in Adoption of mRNA Technology Drive Covid-19 Vaccine Market Growth?

mRNA technology is expected to dominate Covid-19 vaccine market. The revolutionary mRNA technology is emerging as a game-changer in the Covid-19 vaccine landscape, offering unprecedented speed in vaccine development and manufacturing. According to the US FDA, mRNA vaccines demonstrated remarkable efficacy rates of 94-95% in preventing symptomatic Covid-19 infections during initial clinical trials in 2020. Moderna and Pfizer-BioNTech's success with mRNA platforms has sparked increased investment in this technology, with both companies announcing expanded research facilities and enhanced production capabilities throughout 2023 to meet global demand.

The adaptability of mRNA technology has proven crucial in responding to emerging variants, enabling rapid modification of vaccine formulations. The European Medicines Agency reported that over 600 million mRNA vaccine doses were administered in the EU/EEA by December 2023, establishing them as the predominant vaccine type. In February 2024, Moderna announced positive results from its next-generation mRNA platform trials, promising enhanced stability at regular refrigeration temperatures and potentially eliminating the ultra-cold storage requirement that initially challenged distribution.

Will Rise in Adoption of Booster Dose Drive Covid-19 Vaccine Market Growth?

Booster dose is anticipated to hold major share in the Covid-19 vaccine market. The increasing emphasis on booster doses has become a significant driver in the Covid-19 vaccine market, as health authorities worldwide recommend additional shots to maintain immunity levels. The US CDC reported that by January 2024, over 56.5% of eligible adults had received at least one booster dose, highlighting substantial market potential. Major manufacturers like Pfizer-BioNTech and Moderna have adapted their production strategies to meet this sustained demand, with both companies releasing variant-specific boosters targeting the latest strains.

Growing evidence supporting the effectiveness of booster doses in preventing severe illness has strengthened their market position. According to the UK Health Security Agency, booster shots provided 88% additional protection against hospitalization from the Omicron variant in studies conducted through 2023. In March 2024, Moderna announced positive trial results for its combination respiratory booster vaccine, which targets both Covid-19 variants and influenza strains, potentially revolutionizing the seasonal vaccination approach.

Country/Region-wise Acumens

Will Advanced Cold Chain Logistics in North America Drive Covid-19 Vaccine Market Growth?

North America maintains its leadership position in the global Covid-19 vaccine market through robust healthcare infrastructure and substantial government investments in vaccination programs. According to the US CDC, more than 674 million Covid-19 vaccine doses were administered in the United States by December 2023, demonstrating the region's massive vaccine uptake. The presence of major pharmaceutical companies and research institutions has further strengthened North America's market dominance, with recent expansions of manufacturing facilities by Pfizer in Michigan and Moderna in Massachusetts announced in early 2024.

Advanced cold chain logistics and efficient distribution networks have enabled seamless vaccine delivery across the continent, supporting market growth. Health Canada reported that approximately 83% of eligible Canadians completed their primary vaccination series by the end of 2023. Moderna's announcement in March 2024 regarding the establishment of a new research and development hub in Toronto, focusing on next-generation mRNA technologies, reinforces North America's position as a key innovation center for vaccine development.

Will Robust Healthcare Infrastructure Enhance Adoption of Covid-19 Vaccine in Asia Pacific?

North America maintains its leadership position in the global Covid-19 vaccine market through robust healthcare infrastructure and substantial government investments in vaccination programs. According to the US CDC, more than 674 million Covid-19 vaccine doses were administered in the United States by December 2023, demonstrating the region's massive vaccine uptake. The presence of major pharmaceutical companies and research institutions has further strengthened North America's market dominance, with recent expansions of manufacturing facilities by Pfizer in Michigan and Moderna in Massachusetts announced in early 2024.

Advanced cold chain logistics and efficient distribution networks have enabled seamless vaccine delivery across the continent, supporting market growth. Health Canada reported that approximately 83% of eligible Canadians completed their primary vaccination series by the end of 2023. Moderna's announcement in March 2024 regarding the establishment of a new research and development hub in Toronto, focusing on next-generation mRNA technologies, reinforces North America's position as a key innovation center for vaccine development.

Competitive Landscape

The Covid-19 vaccine market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the Covid-19 vaccine market include:

• Pfizer-BioNTech
• Moderna
• AstraZeneca
• Johnson & Johnson (Janssen)
• Novavax
• Sinovac Biotech
• Sinopharm
• Sputnik V (Gamaleya Research Institute)
• Bharat Biotech
• COVAXIN (Bharat Biotech)
• CanSino Biologics
• Zydus Cadila
• Valneva
• Merck & Co.
• Sanofi
• GSK (GlaxoSmithKline)
• CureVac
• Vaxart
• ModernaTX
• Inovio Pharmaceuticals

Latest Developments

• In October 2023, several pharmaceutical companies announced the results of clinical trials for new Covid-19 vaccines aimed at emerging variants, demonstrating increased efficacy and safety profiles.
• In September 2023, the WHO approved a new vaccine platform designed for rapid development and deployment in response to future Covid-19 variants, enhancing global readiness.

Covid-19 Vaccine Market, By Category

• Technology:
• mRNA Technology
• Viral Vector Technology
• Protein Subunit Technology
• DNA Technology
• Application:
• Primary Vaccination
• Booster Doses
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa